The Laos Dabear version of Avatrombopag, as a generic drug option in emerging markets, provides a more accessible treatment choice for patients who need to increase their platelet count.
How much does the Laos Dabear version of Avatrombopag cost?
The Laos Dabear version of Avatrombopag is available in a specification of 20mg*30 tablets/box, priced at approximately $46. The specific price may be affected by various factors and the actual selling price shall prevail.
FDA Approves Avatrombopag for Preoperative Thrombocytopenia in Patients with Chronic Liver Disease
The U.S. Food and Drug Administration (FDA) has approved Avatrombopag (active ingredient: avatrombopag) for use in adult patients with thrombocytopenia caused by chronic (long-term) liver disease who are scheduled to undergo a medical or dental procedure. Thrombocytopenia refers to an abnormally low number of platelets in the blood, which may increase the risk of bleeding during or after surgery. Avatrombopag, as an oral thrombopoietin receptor agonist, stimulates the bone marrow to produce platelets, thereby rapidly increasing platelet counts before surgery and reducing the need for platelet transfusions or emergency hemostatic measures. This approval provides a new treatment option for patients with chronic liver disease-associated thrombocytopenia, especially those who require invasive procedures. It is important to note that Avatrombopag is not indicated for chronic liver disease patients with normal platelet counts, and its safety and efficacy in children have not been established.
Common Adverse Reactions of Avatrombopag
In clinical trials, Avatrombopag has demonstrated a favorable safety profile. Adverse reactions occurring in ≥3% of patients treated with Avatrombopag include: pyrexia (fever), abdominal pain, nausea, headache, fatigue, and peripheral edema (swelling of the hands and feet). These adverse reactions are mostly mild to moderate in severity and are generally transient. Of particular note, Avatrombopag may increase the risk of thrombus (blood clot) formation. Patients with chronic liver disease who also have certain coagulation abnormalities are at higher risk for thrombosis. If patients experience symptoms such as leg swelling, pain or tenderness, rapid heartbeat, abdominal pain or tenderness, shortness of breath, or chest pain after taking the medication, they should inform medical staff immediately, as these may be warning signs of a blood clot. Additionally, the above list does not include all possible side effects; patients should closely monitor their condition during treatment and promptly communicate any discomfort to their physician.
